Loading clinical trials...
Loading clinical trials...
A Phase-II Clinical Trial for First Line Treatment of Stage II/III Covid-19 Patients to Treat Hyperinflammation
Conditions
Interventions
Ruxolitinib
Locations
6
Germany
SRH Wald-Klinikum Gera GmbH
Gera, Germany
University Hospital Jena
Jena, Germany
UKSH, Campus Lübeck
Lübeck, Germany
Klinikum der Landeshauptstadt Stuttgart gKöR
Stuttgart, Germany
Universitätsklinikum Ulm
Ulm, Germany
Schwarzwald-Baar Klinikum Villingen-Schwenningen GmbH
Villingen-Schwenningen, Germany
Start Date
April 22, 2020
Primary Completion Date
July 15, 2021
Completion Date
July 15, 2021
Last Updated
August 13, 2021
NCT07221162
NCT06082518
NCT06631287
NCT06679140
NCT06417762
NCT03830320
Lead Sponsor
University of Jena
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions